Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Carcinoma, Hepatocellular 3Small Cell Lung Carcinoma 2Carcinoma, Non-Small-Cell Lung 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Stage III Lung Non-Small Cell Cancer AJCC v7 1Sarcoma 1Lung Neoplasms 1Liver Neoplasms 1Liver Cirrhosis 1Head and Neck Neoplasms 1Gliosarcoma 1Glioblastoma 1Breast Neoplasms 1

Interventions

Doxorubicin 33Ifosfamide 23Gemcitabine 19pazopanib 18Cyclophosphamide 16Radiotherapy 15pembrolizumab 13Filgrastim 12Docetaxel 12Bevacizumab 10Vincristine 9Sirolimus 9Irinotecan 9Etoposide 9olaratumab 7eribulin 7Sorafenib 7Radiation 7temsirolimus 6Temozolomide 6Mesna 6Magnetic Resonance Spectroscopy 6Cisplatin 6tazemetostat 5cixutumumab 5Trabectedin 5Radiosurgery 5Nivolumab 5Ipilimumab 5Granulocyte Colony-Stimulating Factor 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Sarcoma × fluoromisonidazole × Clear all
NCT01169350 2017-11-17

18F-Fluoromisonidazole and Fludeoxyglucose F 18 PET/CT Patients With Soft Tissue Sarcoma

National Cancer Institute (NCI)

Phase 2 Terminated
8 enrolled 4 charts
Sarcoma

Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡